IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC